Avsnitt
-
David McCall, Senior Editor, BioInsights, spoke to Lee Brown, Healthcare Sector Global Team Leader, Third Bridge Group, on Tuesday, February 6, 2024 to gain his insights into the fast-moving market landscape of advanced therapies. The discussion outlines key recent news and strategic moves from prominent pharma and biotech companies in the field, as well as the prospects for specific technologies such as CRISPR-based genome editing and next-generation CAR-T therapies.
-
Translating the therapeutic promise of cell and gene therapies into clinical reality relies on robust potency assays. However, designing assays that accurately reflect the complex mechanisms of these therapies can feel like chasing a moving target. Here, Charlotte Barker, Editor, Cell & Gene Therapy Insights, speaks with Giorgio Zenere, CMC technical project lead in the Global QC Technology Innovation Team, Kite Pharma, and Dirk Windgassen, Director of Analytical Development, Miltenyi Biotec, to discuss best practices and future trends in developing potency assays for cell and gene therapies.
-
Saknas det avsnitt?
-
Lauren Coyle, Commissioning Editor, Cell & Gene Therapy Insights, talks with Suman Subramanian, Head of Commercial Operations, Catalent Cell and Gene Therapy, to discuss the major achievements in the gene therapy market in 2023, with a focus on reliable manufacturing processes and strategies to enhance predictability while reducing waste in gene therapy manufacturing.
-
Lauren Coyle, Commissioning Editor, Immuno-Oncology Insights, speaks with André Freitas, Senior Lecturer (University of Manchester) and Research Group Leader (Idiap Research Institute/National Biomarker Centre), about the intersection of generative AI and experimental cancer treatments, with a focus on clinical trials, regulatory considerations, and leveraging emerging technologies for a transformative impact in I-O.
-
Lauren Coyle, Commissioning Editor, Immuno-Oncology Insights, speaks to Joe Chang, Clinical Thoracic Oncologist, MD Anderson Cancer Center, University of Texas, who discusses his team’s pioneering work in combining radiation therapy with immunotherapy for lung cancer treatment. He highlights the challenges and promises of optimizing radioimmunotherapy combinations, emphasizing the importance of personalized treatment approaches and collaboration across disciplines to improve patient outcomes.
-
As excitement around the evolving field of mRNA continues to grow, there remain some
fundamental questions to be answered. David McCall, Senior Editor, Nucleic Acid Insights, spoke with Monash University’s Colin Pouton, Professor of Pharmaceutical Biology and Angus Johnston, Associate Professor, ARC Future Fellow about the key limitations and unknowns of current mRNA delivery approaches, and critical areas for further research and innovation to propel the field forward. -
Lauren Coyle, Commissioning Editor, Immuno-Oncology Insights, interviews Katie Campbell, Postdoctoral Fellow, Cancer Research Institute, about her current research on genomics, transcriptomics, and spatial profiling to address challenges in the I-O field.
-
With the potential for avian influenza to transmit and spread amongst humans, an effective vaccine to increase pandemic preparedness is a global priority. Charlotte Barker, Editor, Vaccine Insights, speaks with Mathilde Richard, Principal Investigator & Associate Professor at Erasmus MC, about investigating antigenic evolution of avian influenza viruses, developing better vaccines, and the need for proactive measures to ensure global preparedness in the face of evolving influenza threats.
-
Lauren Coyle, Editor, Immuno-Oncology Insights, speaks to Yvonne McGrath, Chief Scientific Officer, iTeos Therapeutics, about the current and emerging novel targets and pathways for the use of cancer therapy in the I-O field with a focus on small molecules and antibody targets.
-
Lauren Coyle, Editor, Immuno-Oncology Insights, speaks with Raoul Santiago, Clinical Investigator and Associate Professor of Pediatric Hematology and Oncology, University Hospital Center, Laval University, to discuss the role of multiomics in the I-O setting and how these tools can be leveraged to improve pediatric cancer care.
-
The cell and gene therapy space poses a number of unique challenges when it comes to facility design. In this episode, Róisin McGuigan, Editor, BioInsights, speaks to Yposkesi’s Louis-Marie De Montgrand and Morad El Gueddari to discuss the key considerations for designing an advanced therapy manufacturing facility that can meet the needs of future commercial demand.
To read this interview and access lots more content, visit the Cell and Gene Therapy Insights website. -
In this episode, Charlotte Barker, Editor, BioInsights, will be discussing the future of AAV-based gene therapy manufacturing with Elie Hanania, VP of Process Development Viral Vector Technologies at Avid Bioservices, and Ratish Krishnan, Senior Strategy Consultant at Merck Life Sciences.
-
The application of lipid nanoparticles (LNPs) as a non- viral delivery system for advanced therapies, in conjunction with RNA-based medicines, is set to revolutionize the field. In this episode, David McCall, Senior Editor, BioInsights, speaks to Adrian Bot, Chief Scientific Officer and Executive Vice President of R&D, Capstan Therapeutics, about the potential of these tools to drive the burgeoning in vivo cell therapy space in particular, and the broader gene medicine field in general.
-
David McCall, Senior Editor, BioInsights, speaks to Geeta Vemuri, Founder and Managing Partner, Agent Capital, about her VC company's portfolio of advanced therapy investments, and the keys to obtaining funding in a difficult environment. (From an interview conducted on February 22nd, 2023).
-
While attractive from an initial cost perspective, performing early development in a cell culture substrate that does not match a therapy’s final manufacturing platform can have critical implications on development timelines. In this podcast, Charlotte Barker, Editor, BioInsights, speaks to Dalip Sethi, Director of Scientific Affairs, Terumo BCT, about best practices for scaling up cell culture substrate.
-
In this episode, Róisin McGuigan, Editor, Immuno-Oncology Insights, speaks with Eran Ophir, Chief Scientific Officer, Compugen, and Yaron Turpaz, Senior Vice President and Senior Advisor, Data and Informatics Solutions, Compugen, about the advantages of using multiomic and computational approaches for the discovery of novel targets and mechanisms of action (MoA) of novel drug candidates in immuno-oncology.
-
Charlotte Barker (Editor, BioInsights) speaks with Curate Biosciences’ CEO David Backer and CTO Tony Ward about the need for CAR-T cell therapy manufacturing to evolve, and how a new cell separation technique could boost efficiency.
-
Charlotte Barker, Editor, Vaccine Insights, speaks with Ed Lavelle, Professor, Trinity College Dublin, about our growing understanding of adjuvant mechanisms, his work on developing mucosal vaccines, and why size matters for nanoparticles’ adjuvant effects.
-
Non-viral methods for ex vivo cell & gene therapy: is the future non-viral? In this episode, Valeria Annibaldi and Andrea Toell discuss the types and benefits of non-viral methods for ex vivo cell and gene therapy in addition to the readiness of electroporation-based technologies for use in GMP manufacturing.
To read this interview and access lots more content, visit the Cell and Gene Therapy Insights website - Visa fler
